Cargando…
Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2
[Image: see text] Overexpression of the receptor tyrosine kinase EphA2 is invariably associated with poor prognosis and development of aggressive metastatic cancers. Guided by our recently solved X-ray structure of the complex between an agonistic peptide and EphA2-LBD, we report on a novel agent, t...
Autores principales: | Baggio, Carlo, Udompholkul, Parima, Gambini, Luca, Pellecchia, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706575/ https://www.ncbi.nlm.nih.gov/pubmed/36331527 http://dx.doi.org/10.1021/acs.jmedchem.2c01391 |
Ejemplares similares
-
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
por: Salem, Ahmed F., et al.
Publicado: (2020) -
Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
por: Udompholkul, Parima, et al.
Publicado: (2021) -
Reduction of Circulating
Cancer Cells and Metastases
in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug
Conjugate
por: Salem, Ahmed F., et al.
Publicado: (2018) -
Mixture-Based Screening
of Focused Combinatorial Libraries
by NMR: Application to the Antiapoptotic Protein hMcl-1
por: Alboreggia, Giulia, et al.
Publicado: (2023) -
Characterization
of a Potent and Orally Bioavailable
Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist
por: Udompholkul, Parima, et al.
Publicado: (2023)